Actionable news
All posts from Actionable news
Actionable news in ACAD: ACADIA Pharmaceuticals Inc.,

10 Must-Know Biotech Stock Events to Close Out 2016

There, investors will see if Bristol can salvage something positive from the failed study, perhaps defining a subset of lung cancer patients who still benefit from Opdivo.

Acadia Pharmaceuticals (ACAD) : Nuplazid

It's too early in the commercial launch of Acadia's Nuplazid in Parkinson's disease psychosis to make any judgments. Add in an already robust $4 billion market value and it helps explain Acadia's flat stock performance since this spring.

Acadia is one of those biotech companies often mentioned as takeout bait because approved products to treat neuro-psychiatric illnesses are a relatively scarce commodity. The company has a chance to tart itself up even more for a possible sale when it reports results from a phase II study of Nuplazid in Alzheimer's disease psychosis -- a potentially blockbuster indication given the growing numbers of older Americans suffering from the memory-robbing disease. The Nuplazid Alzheimer's psychosis study results are expected near the end of the year.

Celgene (CELG) : GED-0301

GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- that form the core of Celgene's...